Blu Pharmaceuticals Opens Puerto Rico Plant
04/14/2010
"The stars aligned for us in Puerto Rico," said Bill Luster, president of Blu Pharmaceuticals. "We were able to acquire a state-of-the-art manufacturing facility for pennies on the dollar of what it would have cost for us to build an operation from the ground up, plus we were able to tap into a highly talented work force."
The Economic Development Bank for Puerto Rico and Small Business Administration extended $10 million in financing to purchase the facility and equipment. The Puerto Rico Industrial Development Company also offered economic incentives to attract Blu.
"In today's tough financing environment, it made a big difference that the Puerto Rican government was willing to partner with us to help finance the project," Luster said.
Blu Caribe will produce seven different drugs, including ciprofloxacin, an anthrax antidote. It also plans to open a research and development segment. Blu supplies generic drugs to wholesalers, group purchasing organizations, mail order pharmacies, and government agencies including the Veteran's Administration, Bureau of Prisons, Indian Health Services, and the Department of Defense.
Project Announcements
SLB Expands Shreveport, Louisiana, Operations
12/18/2025
Eastover Chips Plans Eastover, South Carolina, Wood Chipping Operations
12/18/2025
Eli Lilly and Company Plans Huntsville, Alabama, Manufacturing Operations
12/18/2025
Eccalon Plans Detroit, Michigan, Headquarters Operations
12/18/2025
AECI Utility Solutions Plans Boonville, Missouri, Distribution Operations
12/18/2025
DrinkPak Plans Philadelphia, Pennsylvania, Manufacturing Operations
12/18/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025
-
Supply Chain Whiplash Reshapes CRE
Q3 2025